JPMorgan analyst Brian Cheng downgraded Mersana Therapeutics to Underweight from Neutral without a price target after Mersana announced that the UPLIFT clinical trial of upifitamab rilsodotin, or UpRi, did not meet its primary endpoint and the company said it is winding down development efforts with UpRi.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRSN: